Abstract
Nippon Shinyaku Co., Ltd., is an R&D-oriented new-drug manufacturer that celebrated its 100th anniversary in 2019. In recent years, we have had two major R&D products: selexipag, our first global new drug, and viltolarsen, the first antisense nucleic acid drug developed in Japan. This paper describes three aspects of our approach to drug-discovery research: modality in drug discovery, data-driven drug discovery and the promotion of open innovation. Our unique system of driving exploratory research through venture-based organizational management is also described. Under the slogan “creating world-class new drugs” and with the goal of creating original and distinctive pharmaceuticals that will be of great value to patients, we have begun to take on the challenge of the next 100 years.
